Literature DB >> 20538289

Celecoxib combined with atorvastatin prevents progression of atherosclerosis.

Mihir Raval1, Philippe G Frank, Lisa Laury-Kleintop, Guang Yan, Susan Lanza-Jacoby.   

Abstract

BACKGROUND: Increased expression of cyclooxygenase (COX-2) contributes to atherosclerosis. Recent studies suggest that COX-2 inhibitors prevent early plaque development but their effects on established lesions are less clear, while the statins promote plaque stability. The purpose of this study is to investigate whether administering a combination of a COX-2 inhibitor with a statin drug alters plaque progression in apo E-/- mice.
MATERIALS AND METHODS: Apo E-/- mice were fed a Western diet from 6 to 26 wk of age. At 26 wk, the Western diets supplemented with atorvastatin, celecoxib, or atorvastatin plus celecoxib were given for an additional 12 wk.
RESULTS: When the mice were 38 wk of age, the total area occupied by the atherosclerotic lesion was 53% less in the mice fed the combination of atorvastatin + celecoxib P ≤ 0.05) than that of the apo E-/- mice fed the Western diet alone, atorvastatin alone, or celecoxib alone. The decreased extent of atherosclerosis observed in the apo E-/- mice fed the combination of drugs was associated with reduced levels of prostaglandin (PG) E(2,) decreased protein expression of metalloproteinase (MMP)-9, macrophage chemotactic protein (MCP-1), and COX 2, and decreased staining for MMP-9, F4-80 (a marker for macrophages), and vascular cell adhesion molecule (VCAM).
CONCLUSION: This study indicates that using statins with a COX-2 inhibitor reduced the extent of atherosclerosis and inflammatory/cell adhesion molecule levels in the apo E-/- mouse model.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538289     DOI: 10.1016/j.jss.2010.03.011

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Atherosclerosis and rheumatoid arthritis: more than a simple association.

Authors:  Lorenzo Cavagna; Nicola Boffini; Giovanni Cagnotto; Flora Inverardi; Vittorio Grosso; Roberto Caporali
Journal:  Mediators Inflamm       Date:  2012-09-13       Impact factor: 4.711

2.  Novel biphasic role of LipoxinA(4) on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts.

Authors:  Shengxing Zheng; Qian Wang; Qian He; Xiaorong Song; Duyun Ye; Fang Gao; Shengwei Jin; Qingquan Lian
Journal:  Mediators Inflamm       Date:  2011-07-02       Impact factor: 4.711

3.  Dietary Silicon Deficiency Does Not Exacerbate Diet-Induced Fatty Lesions in Female ApoE Knockout Mice.

Authors:  Ravin Jugdaohsingh; Katharina Kessler; Barbara Messner; Martin Stoiber; Liliana D Pedro; Heinrich Schima; Günther Laufer; Jonathan J Powell; David Bernhard
Journal:  J Nutr       Date:  2015-05-13       Impact factor: 4.798

Review 4.  Involvement of Fatty Acids and Their Metabolites in the Development of Inflammation in Atherosclerosis.

Authors:  Stanislav Kotlyarov; Anna Kotlyarova
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

Review 5.  PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review).

Authors:  Hua-Zhong Ying; Qin Chen; Wen-You Zhang; Huan-Huan Zhang; Yue Ma; Song-Zhao Zhang; Jie Fang; Chen-Huan Yu
Journal:  Mol Med Rep       Date:  2017-09-27       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.